Pfizer, a Rs. 1,000 crore Mumbai based pharma multinational company, has posted lower net profit of Rs. 56.03 crore during the fourth quarter ended March 2014 as against Rs. 58.16 crore in the corresponding period of last year, a de-growth of 3.7 per cent. Its net sales also declined by 0.2 per cent to Rs. 251.69 crore from Rs. 252.19 crore. Its pharmaceutical sales increased by 6 per cent to Rs. 251.69 crore from Rs. 237.24 crore in the same period last year.
For the full year ended March 2014, Pfizer's net sales increased by 5.6 per cent to Rs. 1,004 crore from Rs. 948 crore in the previous year. Its EBDITA moved up by 20.8 per cent to Rs. 347.91 crore from Rs. 287.91 crore due to lower employees cost and higher other income. Employees cost declined to Rs. 191 crore from Rs. 211 crore and its other income/other operating income increased by 5.3 per cent to Rs. 216.91 crore from Rs. 206.10 crore.
Pfizer's net profit declined sharply by 56.1 per cent to Rs. 220.85 crore from Rs. 503.20 crore due to gain on sales of animal health business of Rs. 382.62 crore and on sale of investment of Rs. 31.60 crore in the previous year. EPS after adjustment worked out to Rs. 74.01 for the year 2013-14 as against Rs. 168.63 in the previous year.
The company had paid an interim dividend of Rs. 360 per equity share of Rs. 10 each for the year ended March 2014 and the Board has not recommended any further dividend.